(agent study)
1,859,513 results
  • Shedding light on neural learning to rank models for anticancer drug prioritization. [Journal Article]
    PLoS One. 2026; 21(8):e0345854.Sarmeili F, Ghahremani-Nezhad B, … Rabiee HRPlos
  • Learning to Rank (LeToR) methods have gained increasing attention in drug response prediction, offering a direct way to prioritize effective treatments for cancer cell lines. In this study, we systematically benchmark six ranking loss functions, including state-of-the-art listwise methods, and five types of molecular representations across two large-scale drug screening datasets, CTRP and PRISM. …
  • Prevalence, severity and predictors of Antipsychotic-Related Adverse Drug Reactions at the Psychiatry Clinic of a Regional Referral Hospital in Uganda. [Journal Article]
    PLoS One. 2026; 21(8):e0356000.Tumwebaza JM, Bukke SPN, … Yadesa TMPlos
  • CONCLUSIONS: The current study showed that over 6 in 10 participants taking antipsychotics experienced at least one ADR, the majority of which were moderate in severity. Separation from a spouse, bipolar disorder, concomitant use of oral and intramascular antipsychotics were independently associated with ADRs. These findings highlight the need for strengthen monitoring and preventive strategies, particularly among high-risk patients taking antipsychotics. Integration of clinical pharmacists into the psychiatry care teams may further enhance ADR detection, monitoring and management.
  • Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes. [Systematic Review]
    PLoS One. 2026; 21(8):e0354497.Olubodun T, Osundina MA, … Ogundele OOPlos
  • CONCLUSIONS: GLP-1 receptor agonists may induce or worsen gastroparesis in both diabetic and non-diabetic patients, particularly following rapid dose escalation or inappropriate dosing. Awareness of this association is essential for timely diagnosis and management. Withdrawal of the causative agent is central to treatment and is associated with favourable outcomes and reversibility of gastric dysfunction. Careful patient selection, gradual dose titration, and monitoring for persistent gastrointestinal symptoms are recommended to optimise the safe use of GLP-1RAs.